<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655393</url>
  </required_header>
  <id_info>
    <org_study_id>15.02.AMZ</org_study_id>
    <secondary_id>OP095615.AMA - OP095715.AMA</secondary_id>
    <nct_id>NCT02655393</nct_id>
  </id_info>
  <brief_title>A Single and Multiple Dose Study of AMAZ-02 to Evaluate Safety and Pharmacokinetics in Elderly Subjects</brief_title>
  <official_title>A Single (Part A) and Multiple (Part B) Dose Study of AMAZ-02, a Food Derived Ingredient to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile in Healthy Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amazentis SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eurofins Optimed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amazentis SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part A:&#xD;
&#xD;
      The study is a double-blind, randomized, single ascending doses, study in 24 healthy elderly&#xD;
      male and female volunteers. Each subject will be randomized for two subsequent doses in three&#xD;
      cohorts.&#xD;
&#xD;
      Part B:&#xD;
&#xD;
      The study is a double-blind, randomized, multiple ascending doses study in 36 healthy elderly&#xD;
      male and female volunteers. Subjects will be randomized to receive study product or placebo&#xD;
      for 28 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A: Single Ascending Dose study of AMAZ-02 with 3 cohorts (each cohort n=8 subjects,&#xD;
      total n=24 subjects). Cohorts undergo two periods of single dose intervention separated by 3&#xD;
      week washout. Adverse events, clinical biochemistry for safety assessment and plasma and&#xD;
      urine collected for pharmacokinetic measurement for parent and metabolite levels in&#xD;
      circulation.&#xD;
&#xD;
      Part B: Multiple Ascending Dose study with 3 cohorts (each cohort n=12 subjects, total n=36&#xD;
      subjects). 28 day administration with AMAZ-02 for safety, PK and PD assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of AMAZ-02 and its metabolites over time and maximal plasma concentration (Cmax)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure to AMAZ-02 measured as area under the curve (AUC)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-live (t 1/2) of AMAZ-02 and its metabolites</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of AMAZ-02 and its metabolites in urine</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of AMAZ-02 and its metabolites in urine</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression for mitochondrial biomarkers in PBMC</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression for mitochondrial biomarkers in muscle tissue</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Lipid Profile</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Aging</condition>
  <condition>Mitochondrial Dysfunction</condition>
  <condition>Muscle Function</condition>
  <arm_group>
    <arm_group_label>AMAZ-02 250 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of AMAZ-02 soft gel capsules at 250 mg dose, n=8 subjects (6 Active, 2 Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMAZ-02 500 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of AMAZ-02 soft gel capsules at 500 mg dose, n=8 subjects (6 Active, 2 Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMAZ-02 1000 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of AMAZ-02 soft gel capsules at 1000 mg dose, n=8 subjects (6 Active, 2 Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMAZ-02 2000 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of AMAZ-02 soft gel capsules at 2000 mg dose, n=8 subjects (6 Active, 2 Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMAZ-02 500 mg single dose-Food Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of AMAZ-02 admixed in yoghurt at 500 mg dose, n=8 subjects (6 Active, 2 Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMAZ-02 1000 mg single dose-Food Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of AMAZ-02 admixed in yoghurt at 1000 mg dose, n=8 subjects (6 Active, 2 Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMAZ-02 250 mg multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated 28 day dosing of AMAZ-02 soft gel capsules at 250 mg dose, n=12 subjects (9 Active, 3 Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMAZ-02 500 mg multiple 28 day dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated 28 day dosing of AMAZ-02 soft gel capsules at 500 mg dose, n=12 subjects (9 Active, 3 Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMAZ-02 1000 mg multiple 28 day dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated 28 day dosing of AMAZ-02 soft gel capsules at 1000 mg dose, n=12 subjects (9 Active, 3 Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AMAZ-02</intervention_name>
    <arm_group_label>AMAZ-02 1000 mg multiple 28 day dose</arm_group_label>
    <arm_group_label>AMAZ-02 1000 mg single dose</arm_group_label>
    <arm_group_label>AMAZ-02 1000 mg single dose-Food Effect</arm_group_label>
    <arm_group_label>AMAZ-02 2000 mg single dose</arm_group_label>
    <arm_group_label>AMAZ-02 250 mg multiple dose</arm_group_label>
    <arm_group_label>AMAZ-02 250 mg single dose</arm_group_label>
    <arm_group_label>AMAZ-02 500 mg multiple 28 day dose</arm_group_label>
    <arm_group_label>AMAZ-02 500 mg single dose</arm_group_label>
    <arm_group_label>AMAZ-02 500 mg single dose-Food Effect</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and female elderly subject, aged between 61 and 85 years inclusive;&#xD;
&#xD;
          2. Non-smoker subject or smoker of not more than 5 cigarettes a day;&#xD;
&#xD;
          3. Body Mass Index (BMI) between 18 and 32 kg/m2 inclusive;&#xD;
&#xD;
          4. Certified as healthy by a comprehensive clinical assessment (detailed medical history&#xD;
             and complete physical examination);&#xD;
&#xD;
          5. Normal Blood Pressure (BP) and Heart Rate (HR) at the screening visit after 10 minutes&#xD;
             in supine position:&#xD;
&#xD;
               -  95 mmHg ≤ Systolic Blood Pressure (SBP) ≤ 160 mmHg,&#xD;
&#xD;
               -  50 mmHg ≤ Diastolic Blood Pressure (DBP) ≤ 95 mmHg,&#xD;
&#xD;
               -  50 bpm &lt; HR &lt; 80 bpm,&#xD;
&#xD;
               -  Or considered NCs by investigators;&#xD;
&#xD;
          6. Normal ECG recording on a 12-lead ECG at the screening visit:&#xD;
&#xD;
               -  120 &lt; PR &lt; 220 ms,&#xD;
&#xD;
               -  QRS &lt; 120 ms,&#xD;
&#xD;
               -  QTcf &lt; 430 ms for male and &lt; 450 ms for female,&#xD;
&#xD;
               -  No sign of any trouble of sinusal automatism,&#xD;
&#xD;
               -  Or considered NCS by investigators;&#xD;
&#xD;
          7. Laboratory parameters within the normal range of the laboratory (haematological, blood&#xD;
             chemistry tests, urinalysis). Individual values out of the normal range can be&#xD;
             accepted if judged clinically non relevant by the Investigator;&#xD;
&#xD;
          8. Normal dietary habits;&#xD;
&#xD;
          9. Demonstrate sedentary behaviour defined as having an activity category of 1 as&#xD;
             assessed by the International Physical Activity Questionnaire (IPAQ). Activity level&#xD;
             is &lt; 600 MET (metabolic equivalent unit - minutes per week and limited to light&#xD;
             intensity activities.&#xD;
&#xD;
         10. Accept to refrain consuming certain foods and supplements at least two weeks before&#xD;
             inclusion.&#xD;
&#xD;
         11. Comprehension of the nature and purpose of the study and ability to communicate in&#xD;
             person and by telephone in a manner that allows all protocol procedures to be carried&#xD;
             out safety and reliably in the opinion of the investigative site staff&#xD;
&#xD;
         12. Ability to take up to 8 capsules of study medication&#xD;
&#xD;
         13. Signing a written informed consent prior to selection;&#xD;
&#xD;
         14. Covered by Health Insurance System and / or in compliance with the recommendations of&#xD;
             National Law in force relating to biomedical research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic,&#xD;
             renal, metabolic, hematological, neurologic, psychiatric, systemic or infectious&#xD;
             disease;&#xD;
&#xD;
          2. Frequent headaches and / or migraine, recurrent nausea and / or vomiting;&#xD;
&#xD;
          3. Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic&#xD;
             postural hypotension defined by a decrease in SBP or DBP equal to or greater than 20&#xD;
             mmHg within two minutes when changing from the supine to the standing position;&#xD;
&#xD;
          4. Blood donation (including in the frame of a clinical trial) within 2 months before&#xD;
             administration;&#xD;
&#xD;
          5. General anaesthesia within 3 months before administration;&#xD;
&#xD;
          6. Presence or history of drug hypersensitivity, or allergic disease diagnosed and&#xD;
             treated by a physician;&#xD;
&#xD;
          7. Lactose intolerance, milk protein or soy allergy.&#xD;
&#xD;
          8. Inability to abstain from intensive muscular effort;&#xD;
&#xD;
          9. No possibility of contact in case of emergency;&#xD;
&#xD;
         10. Use of any of the prohibited medications as detailed in the concomitant medication&#xD;
             section&#xD;
&#xD;
         11. History or presence of drug or alcohol abuse (alcohol consumption &gt; 40 grams / day);&#xD;
&#xD;
         12. Excessive consumption of beverages with xanthine bases (&gt; 4 cups or glasses / day);&#xD;
&#xD;
         13. Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody,&#xD;
             or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests;&#xD;
&#xD;
         14. Positive results of screening for drugs of abuse;&#xD;
&#xD;
         15. Subject who, in the judgment of the Investigator, is likely to be non-compliant or&#xD;
             uncooperative during the study, or unable to cooperate because of a language problem,&#xD;
             poor mental development;&#xD;
&#xD;
         16. Exclusion period of a previous study;&#xD;
&#xD;
         17. Administrative or legal supervision;&#xD;
&#xD;
         18. Subjects should not have participated in previous clinical trials in the last 3 months&#xD;
             and received compensation beyond a certain approved and predefined limit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathilde Latreille-Barbier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eurofins Optimed</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eurofins Optimed</name>
      <address>
        <city>Gières</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Andreux PA, Blanco-Bose W, Ryu D, Burdet F, Ibberson M, Aebischer P, Auwerx J, Singh A, Rinsch C. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019 Jun;1(6):595-603. doi: 10.1038/s42255-019-0073-4. Epub 2019 Jun 14.</citation>
    <PMID>32694802</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

